United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

csl behring uk ltd - octocog alfa - powder and solvent for solution for injection - 2000unit

United Kingdom - English - myHealthbox

bayer ag -

Philippines - English - FDA (Food And Drug Administration)

helix pharmaceutical inc - thiamine hydrochloride (vitamin b1) , pyridoxine hydrochloride (vitamin b6) , cyanocobalamin (vitamin b12) - solution for injection (im) - 100mg + 100mg + 5mg / 3ml

Australia - English - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - hedera helix, quantity: 8 mg/ml (equivalent: hedera helix, qty 20.4 mg/ml; equivalent: emetine, qty 0.004 mg/g) - oral liquid - excipient ingredients: purified water; glycerol; star anise oil; propylene glycol; hyetellose; sorbitol solution (70 per cent) (non-crystallising); peg-40 hydrogenated castor oil - decrease/reduce/relieve bronchial mucous congestion ; expectorant/clear respiratory tract mucous ; loosen respiratory tract mucous ; decrease/reduce/relieve mild bronchial cough ; soothe respiratory tract mucous membranes/mucous tissue

Australia - English - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - hedera helix, quantity: 7 mg/ml (equivalent: hedera helix, qty 42 mg/ml; equivalent: emetine, qty 0.004 mg/ml) - oral liquid - excipient ingredients: maltitol solution; citric acid; purified water; xanthan gum; potassium sorbate; flavour - decrease/reduce/relieve bronchial mucous congestion ; soothe/calm the chest ; decrease/reduce excess chest phlegm ; loosen chest phlegm ; decrease/reduce excess mucous ; expectorant/clear respiratory tract mucous ; loosen respiratory tract mucous ; decrease/reduce/relieve mild bronchial cough ; decrease/reduce/relieve cough ; enhance/improve/promote/increase cough productivity

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

malaysian pharmaceutical industries sdn. bhd. - hedera helix -

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - matricaria chamomilla, quantity: 10 mg/ml (equivalent: matricaria chamomilla, qty 200 mg/ml); hedera helix, quantity: 2 mg/ml (equivalent: hedera helix, qty 12.5 mg/ml; equivalent: emetine, qty 2 mg/g) - liquids - excipient ingredients: sodium benzoate; citric acid; hyetellose; glycerol; purified water; potassium sorbate; sorbitol solution (70 per cent) (non-crystallising); flavour - traditionally used in western herbal medicine to enhance/improve/promote/increase sleep quality/deep sleep ; expectorant/clear respiratory tract mucous ; decrease/reduce/relieve cough

Australia - English - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - azithromycin dihydrate, quantity: 524 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; triacetin; calcium hydrogen phosphate; titanium dioxide; pregelatinised maize starch; crospovidone; sodium lauryl sulfate; magnesium stearate - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity:,1. lower respiratory tract infections:,acute bacterial bronchitis due to streptococcus pneumoniae, haemophilus influenza or moraxella catarrhalis.,community acquired pneumonia due to streptococcus pneumoniae or haemophilus influenzae in patients suitable for outpatient oral treatment.,community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.,2. upper respiratory tract infections:,acute sinusitis due to streptococcus pneumoniae or haemophilus influenzae.,acute streptococcal pharyngitis. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present.,3. uncomplicated skin and skin structure infections:,uncomplicated infections due to staphylococcus aureus, streptococcus pyogenes or streptococcus agalactiae. abscesses usually require surgical drainage.,4. sexually transmitted diseases: uncomplicated urethritis and cervicitis due to chlamydia trachomatis.,note: at the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. as with other drugs for the treatment of non-gonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required.,azithromycin is also indicated for the treatment of chlamydia trachomatis conjunctivitis and trachoma.,azithromycin is also indicated for the prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with hiv infection and cd4 cell count less than or equal to 75 cells/?l (see precautions). disseminated infection due to mycobacterium avium-intracellulare complex should be excluded by a negative blood culture prior to commencement of therapy.,azithromycin is indicated for use in children for the treatment of the following infections:,1. acute streptococcal pharyngitis/tonsillitis:,note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. the 20 mg/kg azithromycin dose appears to be as effective as penicillin in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present.,2. chlamydia trachomatis conjunctivitis and trachoma in children 12 months or older.

Philippines - English - FDA (Food And Drug Administration)

helix pharmaceutical inc.; distributor: helix pharmaceutical inc. - epoetin alfa - solution for injection (iv / sc) - 2000iu / 0.5ml

Philippines - English - FDA (Food And Drug Administration)

helix pharmaceutical inc.; distributor: helix pharmaceutical inc. - epoetin alfa - solution for injection (iv / sc) - 4000iu + 0.4ml